Erytech Pharma

airplane divert change block no reject direction oath

Pharma

Erytech pivots to drug delivery after lead candidate collapses

Erytech is stepping up its focus on the drug delivery applications of its preclinical extracellular vesicles after halting work on its lead asset.

Nick Paul Taylor Nov 22, 2022 9:15am

Princeton NJ

Catalent is picking up a cell therapy plant in New Jersey

Apr 25, 2022 9:55am